Last reviewed · How we verify
Etanercept 50 mg
At a glance
| Generic name | Etanercept 50 mg |
|---|---|
| Also known as | Embrel, ENBREL, Enbrel |
| Sponsor | Centocor, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- NATIENS: Optimal Management and Mechanisms of SJS/TEN (PHASE3)
- A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders (PHASE1)
- Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etanercept 50 mg CI brief — competitive landscape report
- Etanercept 50 mg updates RSS · CI watch RSS
- Centocor, Inc. portfolio CI